Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-08-2008 | Controversies

Is PET always an advantage versus planar and SPECT imaging?

Authors: Giuliano Mariani, Laura Bruselli, Adriano Duatti

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2008

Excerpt

The article by Abass Alavi and Sandip Basu in this issue of the European Journal of Nuclear Medicine and Molecular Imaging vividly embodies, in a scenario that seems to be easy to reach, the expectations that imaging through positron emission tomography (PET) has raised in the nuclear medicine community at large. In Alavi’s view, this scenario resolutely points to soon-to-come wide availability of a complete armamentarium of PET radiopharmaceuticals capable of substituting virtually all of the single photon agents currently employed. Therefore, the most likely horizon that the author depicts for the future of diagnostic nuclear medicine is PET imaging, with dismal chances for both planar imaging and single photon computed tomography (SPECT) to even survive in the daily clinical routine [1]. …

Alavi A, Basu S. Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time? Eur J Nucl Med Mol Imaging. 2008.

Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–47.PubMedCrossRef

Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005;64:208–15.PubMed

Seibyl JP, Chen W, Silverman DH. 3,4-dihydroxy-6-[¹⁸F]-fluoro-l-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Semin Nucl Med. 2007;37(6):440–50. Nov.PubMedCrossRef

Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [⁶⁸Ga]-DOTA-D Phe¹-Tyr³-Octreotide in comparison to [¹¹¹In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42–8.PubMedCrossRef

Watson E, Stabin M, Stubbs J. Dosimetry of technetium-94m-teboroxime. J Nucl Med. 1994;35:923–4.PubMed

Pentlow KS, et al. Quantitative imaging of Iodine-¹²⁴ PET. J Nucl Med. 1996;37:1557–62.PubMed

Lubberink M, van Schie A, de Jong HWAM, van Dongen GAMS, Teule GJJ. Acquisition settings for PET of ¹²⁴I dministered simultaneously with therapeutic amounts of ¹³¹I. J Nucl Med. 2006;47:1375–81.PubMed

Finn R. Chemistry applied to iodine radionuclides. Handbook of radiopharmaceuticals. Chichester: Wiley; 2003. p. 423–5.

10.

Rault E, Vandenberghe S, Van Holen R, De Beenhouwer J, Staelens S, Lemahieu I. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biother Radiopharm. 2007;22:423–30.PubMedCrossRef

11.

Brambilla M, Matheoud R, Secco C, Sacchetti G, Comi S, Rudoni M, et al. Impact of target-to-background ratio, target size, emission scan duration, and activity on physical figures of merit for a 3D LSO-based whole body PET/CT scanner. Med Phys 2007;34:3854–65.PubMedCrossRef

12.

Vandenberghe S. Three-dimensional positron emission tomography imaging with ¹²⁴I and ⁸⁶Y. Nucl Med Commun. 2006;27:237–45.PubMedCrossRef

13.

Pentlow KS, Graham MC, Lambrecht RM, Cheung N-KV, Larson SM. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys. 1991;18:357–66.PubMedCrossRef

14.

Pentlow KS, Finn RD, Larson SM, Erdi YE, Beattie BJ, Humm JL. Quantitative imaging of Yttrium-86 with PET—the occurrence and correction of anomalous apparent activity in high density regione. Clin Positron Imaging. 2000;3:85–90.PubMedCrossRef

15.

Walrand S, Jamar F, Mathieu I, De Camps J, Lonneux M, Sibomana M, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med. 2003;30:354–61.

16.

Herzog H, Tellmann L, Scholten B, Coenen HH, Qaim SM. PET imaging problems with the non-standard positron emitters Yttrium-86 and Iodine-124. Q J Nucl Med Mol Imaging. 2007;52:159–65.PubMed

17.

Taylor A Jr, Nally JV. Clinical applications of renal scintigraphy. AJR Am J Roentgenol. 1995;164:31–41.PubMed

18.

Unver T, Alpay H, Biyikli NK, Ones T. Comparison of direct radionuclide cystography and voiding cystourethrography in detecting vesicoureteral reflux. Pediatr Int. 2006;48:287–91. Jun.PubMedCrossRef

19.

Mariani G, Boni G, Barreca M, Bellini M, Fattori B, AlSharif A, et al. Radionuclide gastro-esophageal motor studies. J Nucl Med. 2004;45:1004–28.PubMed

20.

Mariani G, Pauwels EKJ, AlSharif A, Marchi S, Boni G, Barreca M, Bellini M, et al. Radionuclide evaluation of the lower gastrointestinal tract. J Nucl Med. 2008;49:776–87.PubMedCrossRef

21.

Katsuhiro U. Clinical evaluation of hepatobiliary scintigraphy. Japan J Med Imaging. 1999;18:111–22.

22.

Shah KK, Shah KK, Fink-Bennett D, Kumar KG, McCaughey RS. Extrahepatic biliary obstruction versus intrahepatic disorder. Differentiation with hepatobiliary scintigraphy and ultrasonography. J Clin Gastroenterol. 1988;10:191–6.PubMedCrossRef

23.

Connolly LP, Treves ST, Bozorgi F, O’Connor SC. Meckel’s diverticulum: demonstration of heterotopic gastric mucosa with technetium-99m-pertechnetate SPECT. J Nucl Med. 1998;39:1458–60.PubMed

24.

Schillaci O, Filippi L, Danieli R, Simonetti G. Single-photon emission computed tomography/computed tomography in abdominal diseases. Semin Nucl Med. 2007;37:48–61.PubMedCrossRef

25.

Weissleder H, Weissleder R. Lymphedema: evaluation of qualitative and quantitative lymphoscintigraphy in 238 patients. Radiology. 1988;167:729–35.PubMed

26.

Vaqueiro M, Gloviczki P, Fisher J, Hollier LH, A Schirger A, Wahner HW. Lymphoscintigraphy in lymphedema: an aid to microsurgery. J Nucl Med. 1986;27:1125–30.PubMed

27.

Mariani G, Moresco L, Viale G, Villa G, Bagnasco M, Canavese G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med. 2001;42:1198–15.PubMed

28.

Mariani G, Gipponi M, Moresco L, Villa G, Bartolomei M, Mazzarol G, et al. Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. J Nucl Med. 2002;43:811–27.PubMed

29.

Mariani G, Giuliano AE, Strauss HW. Radioguided surgery: a comprehensive team approach. New York, NY: Springer; 2008.

30.

Bajc M, Albrechtsson U, Olsson C-G, Olsson B, Jonson B. Comparison of ventilation/perfusion scintigraphy and helical CT for diagnosis of pulmonary embolism; strategy using clinical data and ancillary findings. Clin Physiol Funct Imaging. 2002;22:392–7.PubMedCrossRef

31.

Stein PD, Woodard PK, Weg JG, Wakefield TW, Tapson VF, Sostman HD, et al. Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II investigators. Radiology. 2007;242:15–21.PubMedCrossRef

32.

Forstrom LA, Mullan BP, Hung JC, Lowe VJ, Thorson LM. ¹⁸F-FDG labelling of human leukocytes. Nucl Med Commun. 2000;21:691–4.PubMed

33.

Osman S, Danpure HJ. The use of 2-[¹⁸F]-fluoro-2-deoxy-d-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B. 1992;19:183–90.PubMed

34.

Guhlmann A, Brecht-Krauss D, Suger G, Glatting G, Kotzerke J, Kinzl L, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology. 1998;206:749–54.PubMed

35.

Stumpe KDM, Zanetti M, Weishaupt D, Hodler J, Boos N, von Schulthess GK. FDG positron emission tomography for differentiation of degenerative and infectious endplate abnormalities in the lumbar spine detected on MR imaging. AJR Am J Roentgenol. 2002;179:1151–7.PubMed

36.

Gratz S, Dorner J, Fischer U, Behr TM, Behe M, Altenvoerde G, Meller J, et al. ¹⁸F-FDG hybrid PET in patients with suspected spondylitis. Eur J Nucl Med Mol Imaging. 2002;29:516–24.PubMedCrossRef

37.

De Winter F, Gemmel F, Van de Wiele C, Poffijn B, Uyttendaele D, Dierckx R. 18-Fluorine fluorodeoxyglucose positron emission tomography for the diagnosis of infection in the postoperative spine. Spine. 2003;28:1314–9.PubMedCrossRef

38.

O’Connor MK, Kemp BJ. Single-photon emission computed tomography/computed tomography: basic instrumentation and innovations. Semin Nucl Med. 2006;36:258–66.PubMedCrossRef

39.

Beekman F, Hutton B. Multi-modality imaging on track. Eur J Nucl Med Mol Imaging. 2007;34:1410–4.PubMedCrossRef

40.

Husarik DB, Steinert HC. Single-photon emission computed tomography/computed tomography for sentinel node mapping in breast cancer. Semin Nucl Med. 2007;37:29–33.PubMedCrossRef

41.

Krausz Y, Israel O. Single-photon emission computed tomography/computed tomography in endocrinology. Semin Nucl Med. 2006;36:267–74.PubMedCrossRef

42.

Schillaci O. Single-photon emission computed tomography/computed tomography in lung cancer and malignant lymphoma. Semin Nucl Med. 2006;36:275–85.PubMedCrossRef

43.

Horger M, Bares R. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med. 2006;36:286–94.PubMedCrossRef

44.

Bunyaviroch T, Aggarwal A, Oates ME. Optimized scintigraphic evaluation of infection and inflammation: role of single-photon emission computed tomography/computed tomography fusion imaging. Semin Nucl Med. 2006;36:295–311.PubMedCrossRef

45.

Sodee DB, Sodee AE, Bakale G. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007;37:17–28.PubMedCrossRef

46.

Schillaci O, Filippi L, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med. 2007;37:34–47.PubMedCrossRef

47.

Lee ST, Scott AM. Hypoxia positron emission tomography imaging with ¹⁸F-fluoromisonidazole. Semin Nucl Med. 2007;37:451–61.PubMedCrossRef

48.

Kelly CJ, Brady M. A model to simulate tumour oxygenation and dynamic [¹⁸F]-Fmiso PET data. Phys Med Biol. 2006;51:5859–73.PubMedCrossRef

49.

Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol. 2007;17:861–72.PubMedCrossRef

50.

Halley A, Hugentobler A, Icard P, Porret E, Sobrio F, Lerochais JP, et al. Efficiency of ¹⁸F-FDG and ^99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2005;32:1026–32.PubMedCrossRef

51.

Rodrigues M, Li S, Gabriel M, Heute D, Greifeneder M, Virgolini I. ^99mTc-depreotide scintigraphy versus ¹⁸F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J Clin Endocrinol Metab. 2006;91:3997–4000.PubMedCrossRef

52.

Mariani G, Gulec SA, Rubello D, Boni G, Puccini M, Pelizzo MR, et al. Preoperative localization and radioguided parathyroid surgery. J Nucl Med 2003;44:1443–58.PubMed

53.

Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008;29:193–207.PubMedCrossRef

Title: Is PET always an advantage versus planar and SPECT imaging?
Authors: Giuliano Mariani
Laura Bruselli
Adriano Duatti
Publication date: 01-08-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0814-1

At a glance: The STEP trials

Springer Medicine

Is PET always an advantage versus planar and SPECT imaging?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2008

Quality of planar whole-body bone scan interpretations—a nationwide survey

68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression

Whole body 18fluoro-l-dopa PET–CT: a useful tool for location and surgical guidance in primary carcinoid tumours

PET–MRI synergy in molecular, functional and anatomical cancer imaging

Optimizing interventions for preventing uptake in the brown adipose tissue in FDG-PET

[18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice